IMMUNOLOGICAL METHODS FOR EVALUATION OF PLATELET FUNCTIONS IN THE PATIENTS  WITH CARDIOVASCULAR DISEASES

O. V. Sirotkina; N. A. Bogan’kova; A. B. Laskovets; G. A. Kuharchik; L. B. Gaykovaya; T. V. Vavilova

doi:10.15789/1563-0625-2010-3-213-218

IMMUNOLOGICAL METHODS FOR EVALUATION OF PLATELET FUNCTIONS IN THE PATIENTS WITH CARDIOVASCULAR DISEASES

O. V. Sirotkina, N. A. Bogan’kova, A. B. Laskovets, G. A. Kuharchik, L. B. Gaykovaya, T. V. Vavilova

https://doi.org/10.15789/1563-0625-2010-3-213-218

Full Text:

PDF (Rus) |

Generate QR code

Abstract

The aim of this work was a simultaneous analysis of functional platelet activity using both standard optical aggregometry and flow cytometry, by means of measuring P-selectin and GP IIb-IIIa glycoprotein receptor contents on the surface of ADP-induced platelets. GP IIb-IIIa amounts and P-selectin expression on cell surface are significantly increased on platelets after activation with 10 mcM ADP, both in normal donors and in aspirin-treated patients. In clopidogrel-treated patients, the amounts of expressed P-selectin and GP IIb-IIIa did not change after ADP induction, thus suggesting absence of detectable ADP-induced platelet activation in this group. By means of Spearman criterion, a distinct correlation was found between the P-selectin expression, GP IIb-IIIa contents, and rates of standard ADP-induced aggregation. A combination of standard ADP-induced aggregation/activation of platelets with flow cytometry using FITC or PE-labeled antibodies to P-selectin and GP IIb-IIIa, allowed us to apply immunological approaches to analysis of platelet hemostasis, to propose novel laboratory criteria for evaluation of platelet hyperaggregation, and to detect differential effects of clopidogrel and aspirin.

Keywords

P-selectin expression, GP IIb-IIIa, ADP-induced platelet aggregation, flow cytometry

About the Authors

O. V. Sirotkina

Государственное образовательное учреждение высшего профессионального образования «Санкт-Петербургская государственная медицинская академия им. И.И. Мечникова» Министерства здравоохранения и социального развития РФ Учреждение Российской академии наук Петербургский институт ядерной физики им. Б.П. Константинова РАН
Russian Federation

N. A. Bogan’kova

A. B. Laskovets

G. A. Kuharchik

L. B. Gaykovaya

T. V. Vavilova

References

1. Хайдуков С.В., Зурочка А.В. Вопросы современной проточной цитометрии. Клиническое применение. -Челябинск, 2008. -195 с.

2. Шитикова А.С. Тромбоцитарный гемостаз. -СПб.: Издательство СПб ГМУ, 2000. -227 с.

3. Barsky A.A., Arora R.R. Clopidogrel resistance: myth or reality?//J. Cardiovasc. Pharmacol. Therapeut. -2006. -Vol. 11, N 1. -P. 47-53.

4. Braun O.O., Amisten S., Wihlborg A.-K., Hunting K., Nillson D., Erlinge D. Residual platelet ADP reactivity after clopidogrel treatment is dependent on activation of both the unblocked P2Y1 and the P2Y12 receptor and is correlated with protein expression of P2Y12//Purinergic Signalling. -2007. -Vol. 3. -P. 195-201.

5. Braun O.O., Johnell M., Varenhorst C., James S., Brandt J.T., Jakubowski J.A., Winters K.J., Wallentin L., Erlinge D., Siegbahn A. Greater reduction of platelet activation markers and platelet-monocyte aggregates by prasugrel compared to clopidogrel in stable coronary artery disease//Thromb. Haemost. -2008. -Vol. 100, N 4. -P. 626-633.

6. Cattaneo M. Resistance to antiplatelet drugs: molecular mechanisms and laboratory detection//J. Thromb. Haemost. -2007. -Vol. 5, N 1. -P. 230-237.

7. Еnjeti A.K., Lincz L.F., Seldon M. Detection and measurement of microparticles: an evolving research tool for vascular biology//Semin Thromb Hemost. -2007. -Vol. 33. -N 8. -P. 771-779.

8. Ferguson A., Dokainish H., Lakkis N. Aspirin and clopidogrel response variability//Tex. Heart. Inst. J. -2008. -Vol. 35, N 3. -P. 313-320.

9. Fitzgerald D.J., Maree A. Aspirin and clopidogrel resistance//Hematology. Am. Soc. Hematol. Educ. Program. -2007. -P. 114-120.

10. Gurbel P.A., Tantry U.S. Clopidogrel resistance?//Thromb. Research. -2007. -Vol. 120. -P. 311-321.

11. Hayward C.P.M. Advances in understanding «high on-treatment platelet reactivity»//Thromb. Haemost. -2009. -Vol. 102. -P. 799-800.

12. ISLH 2008, Sydney, Coagulation/Haemostasis Workshop.

13. Koenig W. Haemostatic risk factors for cardiovascular diseases//Eur. Heart. J. -1998. -Vol. 19. -C. 39-43.

14. Oestreich J., Smyth S., Campbell C. Platelet function analisis: at the edge of meaning//Thromb. Haemost. -2009. -Vol. 101. -P. 217-219.

15. Shantsila E., Lip G.Y.H. The role of monocytes in thrombotic disorders//Thromb. Haemost. -2009. -Vol. 102. -P. 916-924.

16. Storey R., JudgeH., Heptinstall S. Inhibition of ADP-induced P-selectin expression and platelet-leukocyte conjugate formation by clopidogrel and the P2Y12 receptor antagonist AR-C69931MX but not aspirin//Thromb. Haemost. -2002. -Vol. 88, N 3. -P. 488-494.

17. Szczeklik A., Musial J., Undas A., Sanak M. Aspirin resistance//J. Thromb. Haemost. -2005. -Vol. 3. -P. 1655-1662.

Review

For citations:

Sirotkina O.V., Bogan’kova N.A., Laskovets A.B., Kuharchik G.A., Gaykovaya L.B., Vavilova T.V. IMMUNOLOGICAL METHODS FOR EVALUATION OF PLATELET FUNCTIONS IN THE PATIENTS WITH CARDIOVASCULAR DISEASES. Medical Immunology (Russia). 2010;12(3):213-218. (In Russ.) https://doi.org/10.15789/1563-0625-2010-3-213-218

This work is licensed under a Creative Commons Attribution 4.0 License.

ISSN 1563-0625 (Print)
ISSN 2313-741X (Online)

Username
Password
	Remember me
Not a user? Register with this site Forgot your password?

User

Medical Immunology (Russia)